万千商家帮你免费找货
0 人在求购买到急需产品
- 详细信息
- 文献和实验
- 技术资料
- 保存条件:
常温
- 保质期:
三年
- 英文名:
pVSV-G
- 库存:
60
- 供应商:
信裕生物
- 规格:
5ug质粒
基本信息
| 质粒类型: | 逆转录病毒包膜质粒 |
|---|---|
| 启动子: | CMV |
| 载体大小: | 6507 bp (查看载体序列) |
| 载体抗性: | Ampicillin (氨苄青霉素) |
订购信息
| 产品编号 | 产品名称 | 规格 | 价格 |
|---|---|---|---|
| XY1470 | pVSV-G | 5ug质粒 |
¥1000.00 |
质粒图谱
载体描述
pVSV-G expresses the G glycoprotein of the vesicular stomatitis virus (VSV-G) under the control of the CMV immediate-early promoter (1). VSV-G is used in pseudotyping of Moloney Murine Leukenia Virus (MMLV)-based retroviral vectors by mediating viral entry. VSV-G interacts with phospholipid components of the target cell membrane and fosters the fusion of viral and cellular membranes (2). VSV-G does not require a cell surface receptor and can serve as a surrogate viral envelope protein. pVSV-G Vector includes IVS, a synthetic intron known to enhance the stability of the mRNA (3), the Col E1 origin of replication and bacterial ampicillin rsistance (Ampr) gene for propagation and antibiotic selection in bacteria.
载体应用
As part of the Retro-X™ Universal Retroviral Expression System (Cat. No. 631530), pVSV-G is cotransfected with a retroviral expression vector into the GP2-293 Packaging Cell Line (4) to produce infectious, replication-incompetent retrovirus. The genes encoding the viral gag and pol proteins are stably integrated into GP2-293. Because the VSV-G envelope protein causes toxicity by fusing cellular membranes, it must be expressed transiently from pVSV-G during packaging (5). Although the resulting virus can infect target cell lines and transmit a gene-of-interest, it cannot replicate because target cell lines lack the viral structural and polymerase/integrase genes. The separate introduction and integration of the viral genes into the packaging cell line and the use of minimal viral sequences in the vector minimize the chance of producing replication-competent virus due to recombination events.
风险提示:丁香通仅作为第三方平台,为商家信息发布提供平台空间。用户咨询产品时请注意保护个人信息及财产安全,合理判断,谨慎选购商品,商家和用户对交易行为负责。对于医疗器械类产品,请先查证核实企业经营资质和医疗器械产品注册证情况。
文献和实验感染细胞的基因组,进行长时间的稳定表达。 (2)服务流程 1)含目的基因的慢病毒RNAi干扰载体的构建和纯化提取; 2)慢病毒干扰载体、pGag/Pol、pRev、pVSV-G四质粒共转染293T细胞; 3)培养48~72h,收集培养上清; 4)病毒的纯化和浓缩(超离和/或超滤); 5)滴度测定、目的基因检定 6)将制得的慢病毒液转导客户的靶细胞,筛选混合稳定细胞株,并检测靶基因的表达。 客户提供 1)表达miRNA/shRNA的质粒(提供测序图谱)或所要
克隆载体 pRCII 转入大肠杆菌为例。TA 克隆载体 pRCII 含有 LacZ 基因,多克隆酶切位点位于其间,当没有外源基因插入 LacZ 基因中时,LacZ 基因的启动子可使此基因编码半乳糖苷酶,从而催化底物 X-gal 发生化学反应,菌落变成蓝色;当外源基因与 pRCII 载体发生连接时,LacZ 基因失活,菌落呈白色;同时该质粒还含有氨苄青霉素耐药基因。根据此特性,白色菌落含有重组质粒。在用这种质粒进行克隆时,转化平板培养基中要加入 0.5 mM IPTG、50 g/mL 氨
突变和化学修饰的耐受性,认为siRNA的5’端相对于3’端具有对突变的较高耐受性。有学者认为正义链3’突出端的任何碱基修饰对siRNA作用效果均无明显影响。还有学者认为与反义链互补的正义链3’端发生1—4个碱基的错配反而有助于增强RNAI的活性。二、siRNA制备方法目前为止较为常用的5种制备siRNAs的方法包括化学合成体外转录长片断dsRNAs经RNase III 类降解 (e.g. Dicer, E. coli, RNase III)siRNA表达载体或者病毒载体在细胞中表达siRNAsPCR制备
技术资料暂无技术资料 索取技术资料




